Clinical trials: B-Cell Lymphoproliferative Disorder
Graft Versus Host Disease, Leukemia
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor bone marrow transplant or peripheral stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00611351
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Nebraska
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
This phase I trial is studying the side effects and best dose of SJG-136 in treating patients with relapsed or refractory acute leukemia, myelodysplastic syndromes, blastic phase chronic myelogenous leukemia, or chronic…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00301769
- Testing
- SJG-136
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-cell Lymphoma
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
The purpose of this study is evaluate the response, safety and tolerability in subjects receiving the investigational drugs, RAD001 and LBH589.
- Trial name
- NCT00978432
- Testing
- RAD001, LBH589, Doublet (RAD001 and LBH589)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Anne Beaven, MD
Lymphoma
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
The overall goal of this clinical research study was to find out which of two different chemotherapy drug combinations, R-CHOP and R-HCVAD, is more effective in treating B-cell lymphoma.
- Trial name
- NCT00290498
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- M.D. Anderson Cancer Center
B-cell Non Hodgkin Lymphoma, Richter's Transformation
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.
- Trial name
- NCT03778073
- Testing
- Cosibelimab, Cosibelimab + Ublituximab + Bendamustine combination
- Where
- 9 sites in United States
- Volunteers
- 18 people
- Sponsor
- TG Therapeutics, Inc.
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Bryostatin and Vincristine in B-Cell Malignancies
This phase I trial is studying the side effects and best dose of bryostatin-1 when given together with vincristine in treating patients with chronic lymphocytic leukemia, non-Hodgkin's lymphoma, or multiple myeloma.
- Conditions
- Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma
- Trial name
- NCT00003166
- Testing
- bryostatin 1, vincristine sulfate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL)
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study of parsaclisib plus investigator's choice of either rituximab or obinutuzumab versus placebo plus investigator's choice of rituximab or…
- Trial name
- NCT04796922
- Testing
- parsaclisib, rituximab, obinutuzumab
- Sponsor
- Incyte Corporation
Chronic Myeloproliferative Disorders, Leukemia
Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases
RATIONALE: Listening to relaxing music during a bone marrow biopsy may be effective in reducing anxiety and pain. PURPOSE: This randomized clinical trial is studying how well music works in reducing anxiety and pain in adult…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00376922
- Testing
- music therapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Wake Forest University Health Sciences
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
In this research study we will start by looking for the highest dose of pyrimethamine that can be given safely to CLL patients without severe or unmanageable side effects.
- Trial name
- NCT01066663
- Testing
- pyrimethamine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, B-Cell
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma.
- Trial name
- NCT00867087
- Testing
- inotuzumab ozogamicin (CMC-544), rituximab
- Where
- 35 sites in United States, France and 4 more
- Volunteers
- 64 people
- Sponsor
- Pfizer
Lymphoma, Leukemia
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Venous Thromboembolic Disease
- Trial name
- HEM-DOAC (NCT07270263)
- Testing
- Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Gdansk
Non-Hodgkin's Lymphoma
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA
KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy…
- Trial name
- NCT07620314
- Testing
- KSVCBD injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Chinese PLA General Hospital
Lymphoma, Lymphoma, B-Cell
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in participants who have high-risk B-cell PTLD in their 2nd…
- Trial name
- NCT06954805
- Testing
- Rituximab, Etoposide, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Jennifer Amengual
Leukemia, B-cell, Lymphoma, Hodgkins
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a procedure that transplants bone marrow cells (stem cells) from a matching donor into a recipient in order to allow the donor stem cells to produce…
- Conditions
- Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins, Lymphoma, B-Cell
- Trial name
- NCT01087294
- Testing
- Allogeneic stem cell transplant, Anti-CD19-chimeric-antigen-receptor-transduced T cells, Leukapheresis
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood transplant helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00602693
- Testing
- umbilical cord blood transplantation, Allopurinol, fludarabine phosphate
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors…
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor
- Trial name
- NCT01088763
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 12 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
MALT Lymphoma
Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
The activity of monotherapy with Lenalidomide will be evaluated in patients with lymphoma of the mucosa associated lymphoid tissue (MALT).
- Trial name
- NCT00923663
- Testing
- Lenalidomide
- Where
- Austria
- Volunteers
- 16 people
- Sponsor
- Medical University of Vienna
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
This is a multicenter, single-arm, open-label, Phase 1 study to assess the tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of tazemetostat in participants with relapsed or refractory B-cell…
- Trial name
- NCT03009344
- Testing
- Tazemetostat
- Where
- 2 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Eisai Co., Ltd.
Lymphoma
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
The goal of this clinical research study is to find the highest tolerable dose of the drug lenalidomide (Revlimid, lenalidomide) that can be given with Rituxan® (rituximab) in the treatment of relapsed mantle cell lymphoma.
- Trial name
- NCT00294632
- Testing
- Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Diffuse Large B-Cell Lymphoma
Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)
This study is a prospective, cross-sectional survey to be administered to real patients in remission from DLBCL using a 15-minute postal or online survey.
- Trial name
- NCT02708732
- Where
- United Kingdom
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche